

Michael Soulen

Title:

“Liver-Directed Therapy for neuroendocrine Tumors”

Neuroendocrine tumors are the second most common GI malignancy, with three times the prevalence of liver or pancreatic cancers. 90% of NET patients develop liver metastases, which are the major determinant of survival. Embolization is part of international guidelines for liver-dominant metastases with little guidance as to technique. We will discuss the recently completed RETNET trial, the first global trial comparing standard methods of embolotherapy, and then review ongoing trials of new drugs and combination therapies currently under investigation.